XTL Biopharmaceuticals Ltd. (XTLB) Earnings History
Net Loss23 years of earnings data (2003–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
XTL Biopharmaceuticals Ltd. (XTLB) Earnings Overview
As of November 8, 2026, XTL Biopharmaceuticals Ltd. (XTLB) reported trailing twelve-month net income of -$7M, reflecting -566.7% year-over-year growth. The company earned $-16.00 per diluted share over the past four quarters.
Looking at the long-term picture, XTLB's historical earnings data spans multiple years. The company achieved its highest annual net income of $3M in fiscal 2018.
XTL Biopharmaceuticals Ltd. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NRXP (-$23M net income, -2336.5% margin), SIGA (-$3M net income, 24.6% margin), BFRI (-$6M net income, -25.3% margin), XTLB has comparable earnings metrics. Compare XTLB vs NRXP →
XTLB Earnings vs Peers
Earnings metrics vs comparable public companies
XTLB Historical Earnings Data (2003–2025)
23 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$7M | -578.6% | -$2M | $-16.00 | - | - |
| 2024 | -$1M | -57531.9% | -$2M | $-2.40 | -227.7% | -481.6% |
| 2023 | $-1,782 | +99.9% | $-765,000 | $-30.00 | - | - |
| 2022 | -$1M | -409.9% | $-880,000 | $-4.00 | - | - |
| 2021 | $435,000 | +155.6% | -$1M | $1.12 | - | - |
| 2020 | $-782,000 | +41.9% | $-948,000 | $-9.12 | - | - |
| 2019 | -$1M | -145.1% | $-842,000 | $-4.16 | - | - |
| 2018 | $3M | +482.3% | $-793,000 | $9.28 | - | - |
| 2017 | $-781,000 | +69.3% | -$1M | $-2.72 | - | - |
| 2016 | -$3M | +41.0% | -$3M | $-14.88 | - | - |
| 2015 | -$4M | -70.6% | -$4M | $-104.32 | - | - |
| 2014 | -$3M | -2.1% | -$2M | $-69.76 | - | - |
| 2013 | -$2M | -78.1% | -$3M | $-71.04 | -104.5% | -122.2% |
| 2012 | -$1M | -15.2% | -$2M | $-40.96 | -148.2% | -251.2% |
| 2011 | -$1M | +4.0% | -$1M | $-37.76 | - | - |
| 2010 | -$1M | -148.6% | -$1M | $-71.04 | - | - |
| 2009 | $3M | +128.0% | $3M | $92.80 | - | - |
| 2008 | -$9M | +62.9% | -$10M | $-332.80 | -155.7% | -161.5% |
| 2007 | -$25M | -64.8% | -$26M | $-3520.00 | -2749.6% | -2837.4% |
| 2006 | -$15M | -8.0% | -$16M | $-2432.00 | -3333.0% | -3534.4% |
| 2005 | -$14M | +14.9% | -$14M | $-266.24 | -438.4% | -449.8% |
| 2004 | -$16M | -15.3% | -$17M | $-384.00 | -476.9% | -485.7% |
| 2003 | -$14M | - | $15M | $-4096.00 | - | - |
Download Data
Export XTLB earnings history in CSV or JSON format
Free sign-in required to download data
XTLB Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
23+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
XTLB — Frequently Asked Questions
Quick answers to the most common questions about buying XTLB stock.
What is XTLB earnings per share (EPS)?
XTLB trailing twelve-month (TTM) diluted EPS is $-16.00, reflecting -566.7% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2003 to 2025 is available in the table on this page.
What is XTL Biopharmaceuticals Ltd.'s net income?
XTL Biopharmaceuticals Ltd. (XTLB) trailing twelve-month net income is $-7M as of 2025. Earnings declined -566.7% year-over-year.
Is XTLB profitable?
XTLB is not currently profitable on a TTM basis, reporting a net loss of $-7M. Net margin is N/A. Investors should monitor for a return to profitability.
What is XTLB's earnings growth rate?
XTLB compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2003 to 2025.
What are XTLB's profit margins?
XTL Biopharmaceuticals Ltd. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -269.0%.
Is XTLB growing earnings?
XTLB earnings are declining — EPS fell -566.7% year-over-year. TTM net income dropped to $-7M. This contrasts with the 5-year CAGR of N/A.
What was XTLB's best earnings year?
XTL Biopharmaceuticals Ltd.'s highest annual net income on record is $3M, achieved in fiscal year 2018. Earnings history on this page spans 2003 to 2025 and includes all annual and quarterly figures.
What were XTLB's earnings last quarter?
XTLB's most recent reported quarter was Q4 2024. Net income was $-255000.00 with diluted EPS of $-0.64. For a full breakdown of all quarters, see the quarterly earnings table on this page.